


IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?


Department director Øyvind Melien

Assessment interventions, Norwegian Institute of Public Health (NIPH)

BREAKOUT SESSION 2 Monday, November 12, 2018 15:45 - 16:45


Changing landscape changing paradigms





Expectations - Driving forces -Trends

Example from Norway: Present model HTA processes



Future perspectives

The needs for patients and healthcare

Given limited resources and budgets an increased focus on fundamental and unmet needs is likely to be expected to guide areas and technologies for evaluation


- Further development/refinement of instruments for selection of topics - Prioritization criteria (e.g. severity of disease) corresponding to criteria for healthcare in general

- The future impact of personalized medicine may expand the understanding of unmet needs both at individual and system level

ISPOR Panel 2018 Barcelona

Future perspectives

Need to strenghten the life cycle perspective




Future perspectives

Need to improve and extend data collection

Need to improve and extend the data platform for evaluation to correspond to the life cycle of medical technologies allowing for assessments and reassessments of value including


> **Clinical research data** Health data **Patient experiences**

> > ISPOR Panel 2018 Barcelona



Novel instrument for collecting data from health care:






Future perspectives

Need for broader involvement and dialogue throughout the life cycle

Strengthen dialogue between industry, regulatory authorities, HTA bodies, payers, patient representatives and other stakeholders from an early stage



www.isportorg

ISPOR

Ongoing project

International Initiatives on the Assessment of the Value of Medical Technologies

• Objective:

 Identify the current role of HTA; and other tools/ approaches/methods used to assess the value of medical technologies globally and locally; and develop reflections for a future role that HTA could have in assessing medical technologies throughout their lifecycle to inform decisions and healthcare policies.

· Recommendation:

 There is a need to explore more closely how to utilize and adapt HTA as a supportive tool in the life cycle of medical technologies to benefit patients, health systems and society, and consider the value of other tools and initiatives on novel value frameworks to inform decisions and reach policy objectives.